% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • Dooper55 Dooper55 Jun 4, 2012 11:25 AM Flag

    OMER mentions on June 4th

    A couple more OMER mentions today ......... excerpts provided
    (OMER also had an odd temporary bump early today to $10.78/share.)
    ********************************************************* … lnk0000001

    4 Biotech Gems with Long-Term Bullish Potential

    "Brozak brings up Omeros Corp. (NASDAQ: OMER), which reported highly favorable results in mid-March from its phase 3 trial of 405 patients with its lead candidate OMS302 in patients undergoing intraocular lens replacement (ILR) surgery. The trial met its primary endpoint of maintenance of intraoperative pupil dilation with an unusual statistical significance score of p<0.00001 which represents clear superiority to the placebo control arm of the study. Brozak refers to the results as "stellar" and tells me the market for this product is significant. This year, 3.6 million (3.6M) ILR procedures will be done in the U.S., and 20M are expected worldwide with an annual growth rate of 3–4%. One reason Brozak likes the company is that OMS302 is a proprietary combination of an anti-inflammatory and a dilating agent that have been used in ophthalmologic surgery for more than 15 years. That sounds like a de-risked opportunity. He rates the company a Strong Buy with a $20 target price." … urce=yahoo

    5 Biotech Stocks That Could Be Included In The Russell 2000

    "Omeros Corporation (OMER) has returned a 150% gain in 2012 climbing to a market cap of more than $225 million. As a result of the company's large YTD gains, it is now eligible to be included in the Russell 2000 [June 8 event?]. An inclusion in the index would be beneficial to the company since it has few institutional investors, with 16%. The stock trades with particularly low volume, so being included in the index will help by creating volume and adding exposure for the company.

    Omeros has had a number of encouraging developments in 2012 leading to its rally. It announced successful results from its late-stage trial of OMS302, followed by a patent and upgrades for the stock. The company is now enrolling patients for its second late-stage trial and has significantly increased its number of class A orphan GPCR's, which are important for the development of new drugs."

11.52+0.12(+1.05%)Sep 27 4:00 PMEDT